FDA Restricts Cell Therapeutics Drug Trial Following Death

Law360, New York (June 24, 2013, 3:42 PM EDT) -- The U.S. Food and Drug Administration has restricted clinical studies of Cell Therapeutics Inc.’s experimental blood cancer drug tosedostat after a patient died during a trial, blocking new trial participants from enrolling until the matter is fully investigated, the drugmaker announced Monday.

According to a filing made with the U.S. Securities and Exchange Commission, the FDA notified the Seattle-based cancer drug specialist on June 17 that it had put a partial hold on clinical work underpinning CTI’s investigational new drug application for tosedostat following the patient...
To view the full article, register now.